Optimization of Aminoglycoside Therapy

Optimization of aminoglycoside therapy.

Aminoglycosides are experiencing a resurgence in use because of the spread of multiresistant Gram-negative pathogens. Use of these agents is attended by the occurrence of nephrotoxicity. Aminoglycoside optimization of dose can be defined as the dose having the highest likelihood of a good outcome and the lowest likelihood of toxicity. We have defined the metric Δ as the difference between the l...

Optimal Aminoglycoside Therapy Following the Sepsis: How Much Is Too Much?

Severe sepsis and septic shock are major problems as the result of high rates morbidity andmortality in intensive care units (ICUs). In the presence of septic shock, each hour of delay inthe administration of effective antibiotics is associated with a measurable increase in mortality.Aminoglycosides are effective broad-spectrum antibiotics that are commonly used in ICUs forthe treatment of life...

Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases

Nonsense mutations are quite prevalent in inherited diseases. Readthrough drugs could provide a therapeutic option for any disease caused by this type of mutation. Geneticin (G418) and gentamicin were among the first to be described. Novel compounds have been generated, but only a few have shown improved results. PTC124 is the only compound to have reached clinical trials. Here we first investi...

Renal impairment following aminoglycoside therapy in cystic fibrosis.

Cystic fibrosis (CF) is a chronic respiratory, life limiting illness in the Caucasian population. Chronic infection with Pseudomonas aeruginosa occurs in more than 80% of adults and this contributes to deterioration in lung function over time. A reported long term complication includes renal impairment from presumed cumulative aminoglycoside antibiotics. Aminoglycosides are highly effective aga...

Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections.